Peripheral vertigo and appropriate use of Betahistine to improve outcomes
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242978Keywords:
Betahistine, Peripheral vertigo, Histaminergic systemAbstract
Vertigo, characterized by a spinning or whirling sensation, is a common condition with a prevalence of 4.9% in the general population. It is caused by dysfunction in the vestibular system and can be classified as peripheral or central. Common causes of peripheral vertigo include benign paroxysmal positional vertigo (BPPV), Meniere's disease, and vestibular neuritis. Betahistine hydrochloride, a structural analog of histamine, is a commonly used treatment for peripheral vertigo. It acts as both a histamine H1 antagonist and a partial inverse agonist, improving cochlear blood flow and inhibiting vestibular neuronal firing. Betahistine has been shown to be effective in controlling symptoms, reducing frequency and intensity of vertigo attacks, and improving quality of life.
References
Strupp M, Churchill GC, Naumann I, Mansmann U, Al Tawil A, Golentsova A, et al. Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST). Front Neurol. 2023;14:1271640.
Alcocer RR, José JGL, Romero AN, Nuñez JLC, Montoya VR, Deschamps JJ, et al. Use of betahistine in the treatment of peripheral vertigo, Acta Oto-Laryngologica.2015;135(12):1205-11.
Bhattacharyya N, Gubbels SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, et al. Clinical practice guideline: benign paroxysmal positional vertigo (Update). Otolaryngol Head Neck Surg. 2017;156:1-47.
Kao CL, Hsieh WL, Chern CM, Chen LK, Lin MH, Chan RC. Clinical features of benign paroxysmal positional vertigo (BPPV) in Taiwan: differences between young and senior age groups. Arch Gerontol Geriatr. 2009;49:50–4.
Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: Journal of Vestibular Research. 2013;13:139-51.
Lacour M, Helmchen C, Vidal PP. Vestibular compensation: the neuro-otologist's best friend. J Neurol. 2016;263:54-64.
Pollard, JC Schwartz. Histamine neuronal pathways and their function, Trends Neurosci. 1987;10:86-9.
J Claes, PH van de Heyning. A review of medical treatment for Menière’s disease, Acta Otolaryngol. 2000;544:34-9.
Jeong SH, Kim JS, Kim HJ, Choi JY, Koo JW, Choi KD, et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: a randomized trial. Neurology. 2020;95:1117-25.
Califano L, Salafia F, Mazzone S, Melillo MG, Califano M. Anterior canal BPPV and apogeotropic posterior canal BPPV: two rare forms of vertical canalolithiasis. Acta Otorhinolaryngol Ital. 2014;34:189-97.
Brevern M, Seelig T, Radtke A, Tiel-Wilck K, Neuhauser H, Lempert T. Short-term efficacy of Epley's manoeuvre: a double-blind randomised trial. J Neurol Neurosurg Psychiatry. 2006;77:980–2.
Gordon CR, Gadoth N. Repeated vs single physical maneuver in benign paroxysmal positional vertigo. Acta Neurol Scand. 2004;110:166–9.
Özgirgin ON, Kingma H, Manzari L, Lacour M. Residual dizziness after BPPV management: exploring pathophysiology and treatment beyond canalith repositioning maneuvers. Front Neurol. 2024;15:1382196.
Ke Y, Ma X, Jing Y, Diao T, Yu L. Risk factors for residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a systematic review and meta-analysis. Eur Arch Otorrinolaringol. 2022;279:3237–56.
Benny R. Expert opinions regarding neuro-microcirculatory, vestibular and labyrinthine dynamics in benign paroxysmal positional vertigo. Int J Res Med Sci. 2022;10:796-800.
K. Stambolieva and G. Angov, Effect of treatment with betahistine dihydrochloride on the postural stability in patientswith different duration of benign paroxysmal positional vertigo, Int Tinnitus J: 2010;16(1):32-6.
Zamergrad MV, Kunelskaya NL, Guseva AL, Amelin AV, Lilenko SV, Samartcev IN, et al. Sovremennye predstavleniya o roli betagistina v lechenii zabolevanii vestibulyarnoi sistemy [Betahistine in vestibular disorders: current concepts and perspectives]. Vestn Otorinolaringol. 2021;86(2):73-81.
